Headache Research

Headache Research

Migraine is the most common neurological disorder, and it has also been ranked by World Health Organization’s Global Burden of disease as one of the most disabling medical conditions.

In fact, severe migraine was ranked as more disabling than angina, rheumatoid arthritis and paraplegia, and as severe as dementia and quadriplegia. Migraine often has a profound impact on patients’ work and social life.

Through epidemiological and translational research our team has highlighted the importance of understanding the association of migraine with its comorbidities and helped to start to identify possible new biomarkers and drug targets for migraine. 

For instance, our work has shown that obesity increases the risk of episodic migraine by 81 percent, and we are continuing to build on our knowledge of obesity and migraine, especially with respect to age, gender and adipose tissue distribution. 

Our team’s research on migraine and obesity has also brought us closer to discovering a biomarker for headache. Our study results suggest that adiponectin and other obesity-related molecules may affect migraine pathophysiology and serve as targets for migraine-specific drug development. 

The high incidence of migraine provides enables us to conduct large clinical trials into various aspects of migraine pain and new treatments to alleviate it.